SUPN · Healthcare
Supernus Pharmaceuticals
19/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
26
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$2.7B
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Exchange
NasdaqGM
About SUPERNUS PHARMACEUTICALS
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent…
Who's behind the signal
Every informed buyer we can see on SUPN, across all three feeds.
Hedge funds · 5
Millennium Management (Englander)
Increased +26%
Citadel Advisors
Increased +230%
Point72 (Steve Cohen)
Decreased −42%
D.E. Shaw & Co
Decreased −12%
AQR Capital Management
Decreased −22%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 4 on record
Disclosures from 2020-05-28 to 2020-11-13
The newest disclosure we hold for this stock is 2020-11-13.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2020-11-13 | Gilbert Ray Cisneros, Jr. · D-CA | House | Bought | $1,001 - $15,000 |
| 2020-07-17 | Gilbert Ray Cisneros, Jr. · D-CA | House | Bought | $1,001 - $15,000 |
| 2020-06-01 | Gilbert Ray Cisneros, Jr. · D-CA | House | Bought | $1,001 - $15,000 |
| 2020-05-28 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
Not a model pick — but on our radar.
SUPERNUS PHARMACEUTICALS isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
0
New positions
2
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+26%
0.1% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+230%
0.1% of Citadel Advisors's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
−42%
0.1% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−12%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−22%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to SUPERNUS PHARMACEUTICALS
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell SUPERNUS PHARMACEUTICALS or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订